FDA "Drug Facts" Templates Supersede Reference Listed Drug Labeling - FDA
This article was originally published in The Tan Sheet
Executive Summary
Generic drugs approved under ANDAs may conform to "Drug Facts" labeling as it appears in templates posted on FDA's Web site without having to wait for the reference listed drug's labeling to be approved.
You may also be interested in...
FDA OTC Labeling Guidance Allows Flexible Approach To Template Use
OTC drug manufacturers that choose to employ FDA's "Drug Facts" labeling templates do not have to follow them verbatim, the agency says in a guidance published in the Oct. 18 Federal Register
Perrigo labeling deferrals
FDA grants private labeler's request for varying deferral dates from OTC labeling final rule, depending on when agency labeling templates become available (1"The Tan Sheet" Oct. 1, p. 3). In Dec. 11 letter, FDA concludes that based on amount of time it has taken to finalize labeling templates for several ANDA drug products, "we consider your timetable for concurrent implementation of labeling revisions for [these] products to be appropriate." Implementation deferrals apply to clemastine fumarate tablets, doxylamine succinate tablets, pseudoephedrine HCl extended release and minoxidil topical solution, all of which did not have finalized FDA labeling templates as of Oct. 1...
McNeil “Drug Facts” Booklet Pouch Labeling Proposed For Two-Count Sizes
McNeil Consumer Healthcare is requesting a six-month deferral from the OTC labeling final rule requirements to implement "booklet pouch" labeling for two-count sizes of five products